How will TRANSBIG be funded?
Recognising the potential impact of TRANSBIG in breast cancer research, the European Commission has awarded TRANSBIG partial funding under the 6th Framework Programme for Research. As such, all specific references to TRANSBIG must acknowledge this funding. Seven million Euro have been allocated to TRANSBIG, which is approximately one- fifth of the expected budget. Critical additional funding was secured through partnerships with the pharmaceutical industry and diagnostics companies. The pharmaceutical companies currently involved in the MINDACT Trial are Novartis, F. Hoffmann-La Roche and Sanofi-Aventis. The diagnostics company that is a partner in the TRANSBIG consortium is Agendia. To date the project has also received several grants from organizations such as the Breast Cancer Research Foundation, the Susan G Komen Foundation , the Jaqueline Seroussi Memorial Foundation, la Fondation Contre le Cancer, the Prix “Mois du Cancer du Sein” and the EBCC-Breast Cancer Working Group.
